The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML

The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML

Abstract About 25% of patients with acute myeloid leukemia (AML) harbor FMS-like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD) mutations and their prognosis remains poor. Gilteritinib is a FLT3 inhibitor approved by the US FDA for use in adult FLT3-mutated relapsed or refractory AML pat...

Full description

Bibliographic Details
Main Authors: Xinan Qiao, Jun Ma, Tristan Knight, Yongwei Su, Holly Edwards, Lisa Polin, Jing Li, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Jian Wang, Hai Lin, Yue Wang, Liping Wang, Guan Wang, Jeffrey W. Taub, Yubin Ge
Format: Article
Language:English
Published: Nature Publishing Group 2021-06-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-021-00502-7

Internet

https://doi.org/10.1038/s41408-021-00502-7

Similar Items